$RPDL
Rapid Line Inc.

2023 Q2 Form 10-Q Financial Statement

#000168316823003900 Filed on June 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.165K $10.95K
YoY Change -16.28%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.165K -$10.95K
YoY Change -16.28%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.165K -$22.19K -$10.95K
YoY Change -16.28% 2931.42%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.566M shares 3.568M shares 2.500M shares
Diluted Shares Outstanding 3.566M shares 2.500M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.87K
YoY Change
Cash & Equivalents $18.87K $23.07K
Short-Term Investments
Other Short-Term Assets $1.100K
YoY Change
Inventory
Prepaid Expenses $1.096K $1.687K
Receivables
Other Receivables
Total Short-Term Assets $19.97K $24.76K
YoY Change 48441.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $30.40K $32.45K
YoY Change -20.16%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $30.40K $32.45K
YoY Change -20.16%
TOTAL ASSETS
Total Short-Term Assets $19.97K $24.76K
Total Long-Term Assets $30.40K $32.45K
Total Assets $50.37K $57.21K
YoY Change 40.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $5.310K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.305K $4.280K
YoY Change 2277.78%
LONG-TERM LIABILITIES
Long-Term Debt $54.24K
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $54.24K $54.24K
YoY Change 32.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.305K $4.280K
Total Long-Term Liabilities $54.24K $54.24K
Total Liabilities $59.55K $58.52K
YoY Change 42.12%
SHAREHOLDERS EQUITY
Retained Earnings -$32.09K -$22.92K
YoY Change 3031.28%
Common Stock $364.00 $357.00
YoY Change 42.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.182K -$1.316K -$11.43K
YoY Change
Total Liabilities & Shareholders Equity $50.37K $57.21K
YoY Change 40.56%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q2
OPERATING ACTIVITIES
Net Income -$9.165K -$22.19K -$10.95K
YoY Change -16.28% 2931.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.525K -$8.053K
YoY Change -18.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.300K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $2.325K $8.847K
YoY Change -73.72%
NET CHANGE
Cash From Operating Activities -$6.525K -$8.053K
Cash From Investing Activities
Cash From Financing Activities $2.325K $8.847K
Net Change In Cash -$4.200K $794.00
YoY Change -628.97%
FREE CASH FLOW
Cash From Operating Activities -$6.525K -$8.053K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001910975
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-31
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q2 dei Document Type
DocumentType
10-Q
CY2023Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q2 dei Document Period End Date
DocumentPeriodEndDate
2023-04-30
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 dei Entity File Number
EntityFileNumber
333-263739
CY2023Q2 dei Entity Registrant Name
EntityRegistrantName
RAPID LINE INC.
CY2023Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2023Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1646802
CY2023Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
Gieldowa 4A
CY2023Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Warsaw
CY2023Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01-211
CY2023Q2 dei Entity Address Country
EntityAddressCountry
PL
CY2023Q2 dei Country Region
CountryRegion
48
CY2023Q2 dei City Area Code
CityAreaCode
222
CY2023Q2 dei Local Phone Number
LocalPhoneNumber
196622
CY2023Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q2 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3632750 shares
CY2023Q2 us-gaap Cash
Cash
18869 usd
CY2023Q1 us-gaap Cash
Cash
23069 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1096 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1687 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
19965 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
24756 usd
CY2023Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
41000 usd
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
41000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10597 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8548 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
30403 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
32452 usd
CY2023Q2 us-gaap Assets
Assets
50368 usd
CY2023Q1 us-gaap Assets
Assets
57208 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
5305 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
4280 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5305 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4280 usd
CY2023Q2 NONE Director Loan
DirectorLoan
13244 usd
CY2023Q1 NONE Director Loan
DirectorLoan
13244 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
41000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
41000 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
54244 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
54244 usd
CY2023Q2 us-gaap Liabilities
Liabilities
59549 usd
CY2023Q1 us-gaap Liabilities
Liabilities
58524 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3632750 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3632750 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3567750 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3567750 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
364 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
357 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22542 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
21248 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32087 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22921 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-9182 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1316 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50368 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57208 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9165 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10947 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9165 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
10947 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9165 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10947 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9165 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10947 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3566427 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3566427 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2500000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2500000 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
250 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-732 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-481 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10947 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-11428 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3350 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6407 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-14485 usd
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12505 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5575 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7554 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21276 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22190 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1316 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22549 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9165 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-9182 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9165 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10947 usd
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2049 usd
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2049 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-591 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6525 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8053 usd
CY2023Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2022Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
7822 usd
CY2023Q2 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1025 usd
CY2022Q2 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1025 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1300 usd
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2325 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8847 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4200 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-51 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23069 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18869 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32087 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9165 usd
CY2023Q2 us-gaap Notes And Loans Payable
NotesAndLoansPayable
41000 usd
CY2023Q2 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_z46yDkhFXD06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2 us-gaap Notes And Loans Payable
NotesAndLoansPayable
41000 usd
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
5305 usd
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2667500 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2667500 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3292750 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3292750 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3567750 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3567750 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3632750 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3632750 shares
CY2023Q2 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1925 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6738 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6738 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
32087 usd

Files In Submission

Name View Source Status
0001683168-23-003900-index-headers.html Edgar Link pending
0001683168-23-003900-index.html Edgar Link pending
0001683168-23-003900.txt Edgar Link pending
0001683168-23-003900-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
none-20230430.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
none-20230430_cal.xml Edgar Link unprocessable
none-20230430_def.xml Edgar Link unprocessable
none-20230430_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
none-20230430_lab.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rapid_ex3101.htm Edgar Link pending
rapid_ex3201.htm Edgar Link pending
rapid_i10q-043023.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rapid_i10q-043023_htm.xml Edgar Link completed